Acurx Pharmaceuticals Inc (ACXP) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire STATEN ISLAND...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI) PR Newswire STATEN ISLAND...

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications PR Newswire STATEN ISLAND...

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset PR Newswire STATEN ISLAND, N.Y., Nov. 20, 2024 STATEN ISLAND, N.Y., Nov. 20...

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y., Nov. 13, 2024 STATEN...

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific...

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level...